Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ROIV

Roivant Sciences Ltd

Apr 19 • 04:00PM ET

10.46

Dollar change +0.10
Percentage change 0.97	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJH VXF IBB FXH IWP IJK IWF IWR VHT SCHM

Scroll to Statements

Index	-	P/E	2.01	EPS (ttm)	5.21	Insider Own	31.57%	Shs Outstand	760.14M	Perf Week	-4.39%
Market Cap	8.43B	Forward P/E	-	EPS next Y	-1.19	Insider Trans	-1.20%	Shs Float	551.47M	Perf Month	4.50%
Income	4.47B	PEG	-	EPS next Q	-0.28	Inst Own	50.51%	Short Float	5.61%	Perf Quarter	1.06%
Sales	123.24M	P/S	68.40	EPS this Y	554.35%	Inst Trans	2.60%	Short Ratio	4.19	Perf Half Y	5.98%
Book/sh	7.57	P/B	1.38	EPS next Y	-122.71%	ROA	91.47%	Short Interest	30.93M	Perf Year	18.86%
Cash/sh	8.28	P/C	1.26	EPS next 5Y	-	ROE	123.54%	52W Range	8.06 - 13.24	Perf YTD	-6.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.79%	ROI	68.29%	52W High	-21.00%	Beta	1.32
Dividend TTM	-	Quick Ratio	27.77	Sales past 5Y	571.16%	Gross Margin	72.86%	52W Low	29.78%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	27.79	EPS Y/Y TTM	411.84%	Oper. Margin	-850.46%	RSI (14)	43.02	Volatility	2.45% 3.57%
Employees	904	Debt/Eq	0.08	Sales Y/Y TTM	185.76%	Profit Margin	3624.14%	Recom	1.17	Target Price	16.08
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	1322.86%	Payout	-	Rel Volume	0.63	Prev Close	10.36
Sales Surprise	16.89%	EPS Surprise	2051.46%	Sales Q/Q	117.80%	Earnings	Feb 13 BMO	Avg Volume	7.37M	Price	10.46
SMA20	-3.43%	SMA50	-4.37%	SMA200	-1.74%	Trades		Volume	4,664,117	Change	0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-02-24 07:00AM	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million (GlobeNewswire)
Mar-27-24 01:55PM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal) +7.54%
Mar-26-24 06:22PM	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 (PR Newswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
07:04AM	Loading…
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Feb-15-24 02:45AM	Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? (Insider Monkey)
Feb-13-24 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update (GlobeNewswire)
Feb-10-24 02:55AM	Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares (GuruFocus.com)
Jan-30-24 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 (GlobeNewswire)
Dec-27-23 08:05PM	5 High Growth International Stocks to Buy (Insider Monkey)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -7.78%
Dec-14-23 09:00AM	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
02:38AM	5 Stocks Under $20 To Buy Now (Insider Monkey)
08:00AM	Loading…
Nov-27-23 08:00AM	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus (GlobeNewswire)
Nov-14-23 01:00PM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update (GlobeNewswire)
Nov-10-23 08:00AM	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors (GlobeNewswire)
Oct-30-23 05:30PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	This $5 Billion Biotech Home Run Took Less Than a Year (The Wall Street Journal)
Oct-23-23 03:02PM	Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion (Investopedia) -11.02%
10:31AM	Why Is Roivant Sciences (ROIV) Stock Up Today? (InvestorPlace)
09:52AM	Roche acquires Telavant, rights to bowel disease drug (Yahoo Finance Video)
06:55AM	Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion (The Wall Street Journal)
03:49AM	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal (The Wall Street Journal)
01:00AM	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant (GlobeNewswire)
Oct-13-23 08:00AM	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer (GlobeNewswire)
Oct-05-23 05:01AM	Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com) +5.04%
Oct-03-23 07:00AM	Vivek Ramaswamys Former Company Is Doing Just Fine Without Him (The Wall Street Journal)
05:00AM	Loading…
Sep-30-23 05:00AM	Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com)
Sep-26-23 06:00AM	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire) +21.55%
Sep-11-23 08:00AM	Roivant Announces Completion of Redemption of its Outstanding Warrants (GlobeNewswire) -8.65%
Sep-09-23 10:51AM	The Brash Strategy That Made Vivek Ramaswamy a Fortune (The Wall Street Journal)
Aug-17-23 04:05PM	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants (GlobeNewswire)
Aug-14-23 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update (GlobeNewswire)
Aug-03-23 04:05PM	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 (GlobeNewswire)
Aug-02-23 04:05PM	Roivant Announces Redemption of Outstanding Warrants (GlobeNewswire)
Jul-27-23 08:00AM	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohns Disease (GlobeNewswire)
Jul-26-23 10:21AM	Big Short Steve Eisman Says the Stock Market Will Continue Surging as No Recession Signs Emerge Here Are 2 Stocks That Analysts Like (TipRanks)
Jul-13-23 05:50PM	Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion (The Wall Street Journal)
Jul-11-23 08:00AM	Roivant Ranks No. 25 on Fast Companys Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program (GlobeNewswire)
Jun-28-23 08:57AM	UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire) +11.27%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire)
Jun-26-23 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 (GlobeNewswire) -6.33%
Jun-22-23 07:30AM	Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period (GlobeNewswire)
Jun-21-23 05:00PM	Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis (GlobeNewswire)
May-16-23 07:00AM	Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old (GlobeNewswire)
Apr-04-23 07:37AM	Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory (Business Wire)
07:37AM	Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research (Business Wire)
Mar-28-23 08:00AM	Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients (GlobeNewswire)
Mar-15-23 07:45AM	Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old (GlobeNewswire) +7.91%
Mar-14-23 04:07PM	Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis (GlobeNewswire)
08:00AM	Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs (GlobeNewswire)
Mar-07-23 08:00AM	Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement (GlobeNewswire)
Feb-21-23 08:32PM	Roivant Sciences Announces Change to its Board of Directors (GlobeNewswire)
Feb-13-23 04:17PM	Collecting Pharmas Scraps Can Pay Off for This Biotech (The Wall Street Journal)
07:00AM	Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update (GlobeNewswire)
Feb-02-23 09:14PM	Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) -11.12%
Feb-01-23 04:05PM	Roivant Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Jan-30-23 08:00AM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023 (GlobeNewswire)
Jan-04-23 06:05AM	Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations (GlobeNewswire) +5.73%
Dec-07-22 06:30AM	Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant (PR Newswire)
Dec-01-22 08:00AM	Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases (GlobeNewswire) +8.21%
Nov-14-22 07:00AM	Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire)
Nov-10-22 09:00AM	Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC (GlobeNewswire)
Nov-08-22 06:15AM	Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering (GlobeNewswire) -11.19%
Nov-07-22 04:01PM	Roivant Sciences Announces Proposed Public Equity Offering (GlobeNewswire)
Oct-18-22 04:00PM	Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences (GlobeNewswire)
Aug-30-22 07:00AM	Roivant to Participate in September Investor Events (GlobeNewswire)
Aug-16-22 11:44AM	Time To Worry? Analysts Are Downgrading Their Roivant Sciences Ltd. (NASDAQ:ROIV) Outlook (Simply Wall St.)
Aug-15-22 07:00AM	Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire)
Aug-14-22 10:53AM	Investors in Roivant Sciences (NASDAQ:ROIV) from a year ago are still down 56%, even after 16% gain this past week (Simply Wall St.)
Aug-03-22 07:00AM	Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 (GlobeNewswire)
Jul-23-22 09:00AM	Roivant Sciences Ltd.'s (NASDAQ:ROIV) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
Jun-30-22 09:18AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.) -9.35%
Jun-28-22 06:27AM	Roivant, Pfizer unveil Priovant Therapeutics focused on autoimmune disease treatments, Roivant stock surges (MarketWatch)
06:10AM	Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update (GlobeNewswire)
06:00AM	Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus (GlobeNewswire)
Jun-15-22 04:30PM	Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022 (GlobeNewswire) +7.90%
May-24-22 06:00AM	FDA Approves Dermavants VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years (GlobeNewswire) +7.12%
May-19-22 04:30PM	Roivant to Present at Upcoming Investor Conferences (GlobeNewswire)
May-16-22 07:00AM	Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
May-09-22 11:16AM	What Type Of Shareholders Own The Most Number of Roivant Sciences Ltd. (NASDAQ:ROIV) Shares? (Simply Wall St.) -12.71%
May-02-22 07:00AM	Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation (GlobeNewswire)
Apr-20-22 07:00AM	VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders (GlobeNewswire)
Apr-13-22 07:00AM	VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen (GlobeNewswire)
Mar-25-22 08:01AM	Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting (GlobeNewswire)
Mar-24-22 07:00AM	Sanford Burnham Prebys and Roivant Social Ventures Announce Groundbreaking Partnership to Increase Diversity & Inclusion in Biopharma (GlobeNewswire)
Mar-11-22 04:45PM	Roivant to Present at Targeted Protein Degradation Conference (GlobeNewswire)
Mar-07-22 11:18AM	Roivant Sciences (NASDAQ:ROIV) dips 14% this week as increasing losses might not be inspiring confidence among its investors (Simply Wall St.)
Feb-28-22 06:01AM	Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Feb-14-22 07:00AM	Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update (GlobeNewswire) +5.11%
Feb-07-22 07:00AM	Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022 (GlobeNewswire)
Jan-25-22 04:30PM	Roivant to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-05-22 04:30PM	Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.52%
10:39AM	Goldman Sachs Predicts Over 60% Rally for These 3 Stocks (TipRanks)
Dec-16-21 10:00AM	Virtual Reality Startup Nanome Announces Largest Deployment to Date (GlobeNewswire)
Nov-15-21 07:00AM	Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update (GlobeNewswire)
Nov-08-21 04:45PM	Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021 (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & COO	Feb 09 '24	Option Exercise	3.85	96,950	373,258	629,157	Feb 09 09:00 PM
Venker Eric	President & COO	Feb 09 '24	Sale	10.92	96,950	1,058,694	532,207	Feb 09 09:00 PM
Ramaswamy Vivek	10% Owner	Jan 02 '24	Sale	11.05	3,000,000	33,150,000	51,929,426	Jan 03 04:56 PM
Venker Eric	Chief Operating Officer	Oct 05 '23	Sale	10.11	153,027	1,547,103	595,397	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 04 '23	Option Exercise	3.85	153,027	589,154	748,424	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 03 '23	Option Exercise	3.85	606,221	2,333,951	1,201,618	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 03 '23	Sale	10.25	606,221	6,213,765	595,397	Oct 04 09:30 PM
Venker Eric	Chief Operating Officer	Oct 02 '23	Option Exercise	3.85	440,752	1,696,895	1,036,149	Oct 04 09:30 PM
Roivant Sciences Ltd.	Director	Oct 02 '23	Buy	38.00	1,526,316	58,000,008	79,805,331	Oct 04 05:15 PM
Venker Eric	Chief Operating Officer	Oct 02 '23	Sale	10.80	440,752	4,760,122	595,397	Oct 04 09:30 PM
SVF Investments (UK) Ltd	10% Owner	Sep 28 '23	Sale	12.60	10,000,000	126,000,000	73,031,667	Oct 02 09:00 PM
QVT Financial LP	Director by Deputization	Sep 28 '23	Sale	11.55	10,000,000	115,500,000	100,804	Oct 02 08:43 PM
Gold Daniel Allen	Director	Sep 28 '23	Sale	11.55	10,000,000	115,500,000	100,804	Oct 02 08:55 PM
MANCHESTER KEITH S	Director	Sep 28 '23	Sale	11.55	6,896,144	79,650,463	5,023,787	Oct 02 09:05 PM
Venker Eric	President & COO	Sep 27 '23	Option Exercise	3.85	500,000	1,925,000	1,095,397	Sep 29 09:30 PM
Venker Eric	President & COO	Sep 27 '23	Sale	13.02	500,000	6,510,000	595,397	Sep 29 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Sep 08 '23	Option Exercise	6.48	99,350	643,788	297,300	Sep 12 09:30 PM
Venker Eric	Chief Operating Officer	Sep 08 '23	Option Exercise	3.85	106,430	409,756	718,243	Sep 12 09:32 PM
Venker Eric	Chief Operating Officer	Sep 08 '23	Sale	12.19	106,430	1,297,382	611,813	Sep 12 09:32 PM
Kumar Rakhi	Chief Accounting Officer	Sep 08 '23	Sale	12.18	99,350	1,210,083	197,950	Sep 12 09:30 PM
Venker Eric	Chief Operating Officer	Sep 06 '23	Option Exercise	3.85	5,926	22,815	617,739	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Sep 06 '23	Sale	11.85	5,926	70,223	611,813	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Sep 05 '23	Option Exercise	3.85	73,275	282,109	685,088	Sep 06 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Sep 05 '23	Option Exercise	6.48	1,724	11,172	199,674	Sep 07 09:30 PM
Venker Eric	Chief Operating Officer	Sep 05 '23	Sale	11.92	73,275	873,438	611,813	Sep 06 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Sep 05 '23	Sale	12.00	1,724	20,688	197,950	Sep 07 09:30 PM
Venker Eric	Chief Operating Officer	Sep 01 '23	Option Exercise	3.85	14,763	56,838	626,576	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Sep 01 '23	Sale	11.90	14,763	175,680	611,813	Sep 06 09:30 PM
Venker Eric	Chief Operating Officer	Aug 14 '23	Option Exercise	3.85	59,811	230,272	687,729	Aug 16 09:34 PM
Venker Eric	Chief Operating Officer	Aug 14 '23	Sale	11.89	59,811	711,153	627,918	Aug 16 09:34 PM
Venker Eric	Chief Operating Officer	Aug 03 '23	Option Exercise	3.85	44,629	171,822	672,547	Aug 07 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 03 '23	Option Exercise	6.48	3,681	23,853	203,009	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Aug 03 '23	Sale	11.93	44,629	532,424	627,918	Aug 07 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 03 '23	Sale	12.00	3,681	44,172	199,328	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Aug 02 '23	Option Exercise	3.85	16,397	63,128	644,315	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Aug 02 '23	Sale	11.86	16,397	194,468	627,918	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Aug 01 '23	Option Exercise	3.85	61,397	236,378	689,315	Aug 02 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 01 '23	Option Exercise	6.48	336	2,177	199,664	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Aug 01 '23	Sale	11.92	61,397	731,852	627,918	Aug 02 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Aug 01 '23	Sale	12.00	336	4,032	199,328	Aug 03 09:30 PM
Venker Eric	Chief Operating Officer	Jul 31 '23	Option Exercise	3.85	117,372	451,882	745,290	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Jul 31 '23	Sale	11.91	117,372	1,397,901	627,918	Aug 02 09:30 PM
Venker Eric	Chief Operating Officer	Jul 27 '23	Option Exercise	3.85	23,622	90,945	651,540	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 27 '23	Sale	10.98	23,622	259,370	627,918	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 26 '23	Option Exercise	3.85	73,568	283,237	701,486	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 26 '23	Sale	10.91	73,568	802,627	627,918	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 25 '23	Option Exercise	3.85	28,344	109,124	656,262	Jul 27 09:30 PM
Venker Eric	Chief Operating Officer	Jul 25 '23	Sale	10.86	28,344	307,816	627,918	Jul 27 09:30 PM
Venker Eric	President & COO	Jul 24 '23	Option Exercise	3.85	33,081	127,362	677,296	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 24 '23	Sale	10.93	33,081	361,575	644,215	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 21 '23	Option Exercise	3.85	181,998	700,692	826,213	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 21 '23	Sale	11.13	181,998	2,025,638	644,215	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 20 '23	Option Exercise	3.85	159,387	613,640	803,602	Jul 24 09:31 PM
Venker Eric	President & COO	Jul 20 '23	Sale	11.31	159,387	1,802,667	644,215	Jul 24 09:31 PM
Kumar Rakhi	Chief Accounting Officer	Jul 18 '23	Option Exercise	6.48	100	648	82,228	Jul 18 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Jul 18 '23	Sale	12.00	100	1,200	82,128	Jul 18 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Jul 14 '23	Option Exercise	6.48	535	3,467	82,663	Jul 18 09:30 PM
Kumar Rakhi	Chief Accounting Officer	Jul 14 '23	Sale	12.00	535	6,420	82,128	Jul 18 09:30 PM
Sumitomo Chemical Co., Ltd.	10% Owner	Jun 22 '23	Sale	8.60	15,116,277	129,999,982	71,251,083	Jun 26 04:05 PM
VIKING GLOBAL PERFORMANCE LLC	10% Owner	Jun 22 '23	Sale	9.90	13,000,000	128,700,000	641,010	Jun 26 05:10 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 22 '23	Sale	9.90	13,000,000	128,700,000	641,010	Jun 26 05:11 PM
Venker Eric	President & COO	Jun 09 '23	Option Exercise	3.85	299,384	1,152,628	959,481	Jun 09 09:32 PM
Kumar Rakhi	Chief Accounting Officer	Jun 09 '23	Option Exercise	5.12	43,893	224,732	242,475	Jun 13 09:31 PM
Venker Eric	President & COO	Jun 09 '23	Sale	9.91	299,384	2,966,895	660,097	Jun 09 09:32 PM
Kumar Rakhi	Chief Accounting Officer	Jun 09 '23	Sale	9.93	43,893	435,857	198,582	Jun 13 09:31 PM
Venker Eric	President & COO	Jun 07 '23	Option Exercise	3.85	201	774	660,298	Jun 09 09:32 PM
Venker Eric	President & COO	Jun 07 '23	Sale	9.85	201	1,980	660,097	Jun 09 09:32 PM
Venker Eric	President & COO	May 23 '23	Option Exercise	3.85	415	1,598	676,183	May 25 09:30 PM
Venker Eric	President & COO	May 23 '23	Sale	9.85	415	4,088	675,768	May 25 09:30 PM
Venker Eric	President & COO	May 09 '23	Option Exercise	3.85	238,724	919,087	914,492	May 11 09:33 PM
Venker Eric	President & COO	May 09 '23	Sale	9.23	238,724	2,203,423	675,768	May 11 09:33 PM
Venker Eric	President & COO	May 08 '23	Option Exercise	3.85	61,206	235,643	736,974	May 08 09:30 PM
Venker Eric	President & COO	May 08 '23	Sale	8.93	61,206	546,570	675,768	May 08 09:30 PM
Venker Eric	President & COO	May 04 '23	Option Exercise	3.85	88,838	342,026	764,606	May 08 09:30 PM
Venker Eric	President & COO	May 04 '23	Sale	8.30	88,838	737,355	675,768	May 08 09:30 PM
Venker Eric	President & COO	May 03 '23	Option Exercise	3.85	118,760	457,226	794,528	May 03 09:30 PM
Venker Eric	President & COO	May 03 '23	Sale	8.40	118,760	997,584	675,768	May 03 09:30 PM
Venker Eric	President & COO	May 02 '23	Option Exercise	3.85	109,074	419,935	784,842	May 03 09:30 PM
Kumar Rakhi	Chief Accounting Officer	May 02 '23	Option Exercise	3.85	15,517	59,740	215,656	May 03 09:30 PM
Venker Eric	President & COO	May 02 '23	Sale	8.29	109,074	904,223	675,768	May 03 09:30 PM
Kumar Rakhi	Chief Accounting Officer	May 02 '23	Sale	8.42	15,517	130,653	200,139	May 03 09:30 PM
Kumar Rakhi	Chief Accounting Officer	May 01 '23	Option Exercise	3.85	62,219	239,543	262,358	May 03 09:30 PM
Venker Eric	President & COO	May 01 '23	Option Exercise	3.85	61,155	235,447	736,923	May 03 09:30 PM
Kumar Rakhi	Chief Accounting Officer	May 01 '23	Sale	8.58	62,219	533,839	200,139	May 03 09:30 PM
Venker Eric	President & COO	May 01 '23	Sale	8.59	61,155	525,321	675,768	May 03 09:30 PM
Venker Eric	President & COO	Apr 28 '23	Option Exercise	3.85	75,823	291,919	751,591	Apr 28 09:35 PM
Kumar Rakhi	Chief Accounting Officer	Apr 28 '23	Option Exercise	3.85	71,989	277,158	272,128	Apr 28 09:35 PM
Venker Eric	President & COO	Apr 28 '23	Sale	8.47	75,823	642,221	675,768	Apr 28 09:35 PM
Kumar Rakhi	Chief Accounting Officer	Apr 28 '23	Sale	8.47	71,989	609,747	200,139	Apr 28 09:35 PM
Venker Eric	President & COO	Apr 27 '23	Option Exercise	3.85	73,514	283,029	749,282	Apr 28 09:35 PM
Kumar Rakhi	Chief Accounting Officer	Apr 27 '23	Option Exercise	3.86	70,969	273,871	271,108	Apr 28 09:35 PM
Venker Eric	President & COO	Apr 27 '23	Sale	8.51	73,514	625,604	675,768	Apr 28 09:35 PM
Kumar Rakhi	Chief Accounting Officer	Apr 27 '23	Sale	8.51	70,969	603,946	200,139	Apr 28 09:35 PM
Kumar Rakhi	Chief Accounting Officer	Apr 26 '23	Option Exercise	3.92	87,830	344,528	287,969	Apr 28 09:35 PM
Venker Eric	President & COO	Apr 26 '23	Option Exercise	3.85	72,906	280,688	748,674	Apr 28 09:35 PM
Kumar Rakhi	Chief Accounting Officer	Apr 26 '23	Sale	8.68	87,830	762,364	200,139	Apr 28 09:35 PM
Venker Eric	President & COO	Apr 26 '23	Sale	8.66	72,906	631,366	675,768	Apr 28 09:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ROIV

Roivant Sciences Ltd

Upgrade your FINVIZ experience